No, it is not.
We know from the company itself and the clinical trials registry history that the trial was randomised and placebo controlled. Also, that the primary endpoint was PFS and the secondary endpoint was OS.
Last year Dr. Mulholland presented at the New York Academy of Sciences. For PFS, the hazard ratio was 1.1. So those in the vaccine arm did worse than placebo. They did not report the hazard ratio for OS, but the blended mOS was 23.1 months for placebo, while for the vaccine arm it was 22.4 months. This means the vaccine did worse than placebo. So, the trend was to harm, not benefit.
As for the JAMA Oncology paper, you should read the comments left. Also, various expert opinions and papers like these https://www.practiceupdate.com/c/5a1bf484-a4ad-467b-a962-d382404cf951 https://www.practiceupdate.com/c/de89dd7d-9c8f-45fb-aa08-27b5a4a07682 https://www.sciencedirect.com/science/article/pii/S0035378723009190 https://academic.oup.com/neuro-oncology/article/25/4/631/6958519 https://www.nature.com/articles/s41416-023-02194-1
Recent NVCR News
- Novocure to Report Second Quarter 2024 Financial Results • Business Wire • 07/01/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:09:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 10:37:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 10:13:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 09:43:31 PM
- METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival • Business Wire • 06/03/2024 12:00:00 PM
- TIGER-Studie berichtet über neue Überlebensergebnisse der TTFields-Therapie bei neu diagnostizierten Glioblastom-Patienten in Deutschland • Business Wire • 05/24/2024 01:06:00 PM
- TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany • Business Wire • 05/23/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 12:01:17 PM
- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon • Business Wire • 05/02/2024 11:01:00 AM
- Novocure Reports First Quarter 2024 Financial Results • Business Wire • 05/02/2024 11:00:00 AM
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 • Business Wire • 04/24/2024 02:45:00 PM
- Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 • Business Wire • 04/05/2024 11:00:00 AM
- Novocure to Report First Quarter 2024 Financial Results • Business Wire • 04/01/2024 11:00:00 AM
- METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長 • Business Wire • 03/29/2024 12:07:00 AM
- Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs • Business Wire • 03/28/2024 05:51:00 PM
- L’essai clinique de phase 3 METIS a atteint son critère principal, démontrant un allongement statistiquement significatif du délai médian jusqu’à la progression intracrânienne chez les patients porteurs de métastases cérébrales consécutives.. • Business Wire • 03/28/2024 05:50:00 PM
- METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer • Business Wire • 03/27/2024 11:00:00 AM
- INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO • Business Wire • 03/11/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:08:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:39:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:56:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:06:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:43:29 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM